Q-omics provides the consensus-scored PRDM7 profile across patient tissues and cancer cell-line models. PRDM7 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRDM7 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, PRDM7 RNA expression shows 14,711 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KIRP, and TGCT as cancer lineages where PRDM7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRDM7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRDM7 survival associations across molecular data types. PRDM7 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRDM7 RNA expression–survival associations across cancer types. High PRDM7 expression shows unfavorable associations in KIRC, LGG and UVM, but favorable associations in SCLC, READ and DLBC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PRDM7 RNA expression.
This table summarizes PRDM7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for PRDM7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRDM7 shows lower tumor expression in KIRP, KICH and KIRC and higher tumor expression in LIHC, BLCA and LUAD. The KIRP box plot shows higher PRDM7 RNA expression in normal versus tumor tissue (log2 FC = −0.148, t-test p < 0.001).
This table shows molecular features associated with PRDM7 in patient tissues and cancer cell lines. In patient samples, PRDM7 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PRDM7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and SKIN.
